Ovarian Cancer – Bradley Monk, MD, and Robert Figlin, MD, discuss clinical highlights from ESMO 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley Monk, MD, FACOG, FACS, Professor and Director of the Division of Gynecologic Oncology at Creighton University School of Medicine, discuss BRCA1+ ovarian patients, PARP inhibitors and the results of the SOLO-1 clinical trial

Leave a Reply